| Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis. | |
| | |
MedLine Citation:
|
PMID: 3104273 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ten patients with cystic fibrosis (CF) and chronic broncho-pulmonary Pseudomonas aeruginosa infection were given imipenem/cilastatin (100 mg/kg/day) in combination with tobramycin (15 mg/kg/day). Forced vital capacity and forced expiratory volume in the first second improved significantly in nine out of ten patients, and most of the patients improved clinically. P. aeruginosa was not eradicated in any patient and resistance against imipenem developed in all patients during treatment. A concomitant increase in MIC of piperacillin and ceftazidime occurred during treatment. In-vitro bactericidal synergy of imipenem and tobramycin was noted in 57% of pretreatment isolates. Seven patients complained of adverse reactions, mainly gastrointestinal, and treatment of three patients was discontinued after 5, 8, and 12 days of therapy, because of rash or nausea and vomiting. The side effects were considered to be due to imipenem/cilastatin. Because of the rapid development of imipenem resistance despite combination therapy, the high proportion of side effects, and the risk of induction of beta-lactam resistance, imipenem/cilastatin cannot be recommended for routine treatment of CF-patients with P. aeruginosa infection. |
| | |
Authors:
|
S S Pedersen; T Pressler; T Jensen; V T Rosdahl; M W Bentzon; N Høiby; C Koch |
Related Documents
:
|
8040763 - Kyphosis and fractures in children and young adults with cystic fibrosis. 6901713 - Hyperuricosuria in cystic fibrosis patients treated with pancreatic enzyme supplements.... 3079723 - Testicular responsiveness to long-term administration of hcg and hmg in patients with h... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Journal of antimicrobial chemotherapy Volume: 19 ISSN: 0305-7453 ISO Abbreviation: J. Antimicrob. Chemother. Publication Date: 1987 Jan |
Date Detail:
|
Created Date: 1987-05-21 Completed Date: 1987-05-21 Revised Date: 2009-10-28 |
Medline Journal Info:
|
Nlm Unique ID: 7513617 Medline TA: J Antimicrob Chemother Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 101-7 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Anti-Bacterial Agents / metabolism, pharmacology, therapeutic use Bronchopneumonia / complications, drug therapy* Child Chronic Disease Cilastatin Cyclopropanes / metabolism, pharmacology, therapeutic use Cystic Fibrosis / complications* Drug Combinations / metabolism, pharmacology, therapeutic use Drug Synergism Drug Therapy, Combination Female Humans Imipenem Kinetics Male Microbial Sensitivity Tests Penicillin Resistance Piperacillin / pharmacology Pseudomonas Infections / complications, drug therapy*, microbiology Pseudomonas aeruginosa / drug effects Sputum / microbiology Thienamycins / metabolism, pharmacology, therapeutic use Tobramycin / metabolism, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/Cyclopropanes; 0/Drug Combinations; 0/Thienamycins; 32986-56-4/Tobramycin; 61477-96-1/Piperacillin; 74431-23-5/Imipenem; 82009-34-5/Cilastatin; 92309-29-0/cilastatin, imipenem drug combination |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Enhancement of ovulation rate in gilts by increasing dietary energy and administering insulin during...
Next Document: Chequerboard titrations: the influence of the composition of serial dilutions of antibiotics on the ...